

	<b>ACCREDITATION DOCUMENT</b>	<b>F-06/02 Issue Date: 10/08/15 Rev. No: 07 LAB 166</b>
---	-----------------------------------	---

## **Accreditation No: LAB 166**

### **Awarded to**

**Drugs Testing Laboratory, Punjab, Rawalpindi  
Dharmyal Road, Hayal Sharif, Rawalpindi – Pakistan.**

The scope of accreditation is in accordance with the standard specifications outlined in the following page(s) of this document. The accredited scope shall be visible and legible in areas such as customer service, sample-receiving section etc and shall not mislead its users.

The accreditation was first time granted on **27-12-2018** by Pakistan National Accreditation Council.

The laboratory complies with the requirements of **ISO/IEC 17025:2017**.

The accreditation requires regular surveillance, and is valid until **26-12-2021**.

The decision of accreditation made by Pakistan National Accreditation Council implies that the organization has been found to fulfill the requirements for accreditation within the scope.

The organization however, itself is responsible for the results of performed measurements/tests.

**PAKISTAN NATIONAL ACCREDITATION COUNCIL**

**30-04-2020**

Date

\_\_\_\_\_  
Director General

	<b>ACCREDITATION DOCUMENT</b>	<b>F-06/02</b> <b>Issue Date: 10/08/15</b> <b>Rev. No: 07</b> <b>LAB 166</b>
---	-----------------------------------	---

### Testing Laboratory.

Accreditation Scope of Drugs Testing Laboratory, Punjab, Rawalpindi –  
Pakistan

Permanent laboratory premises

Materials/Products tested	Testing field (e.g. environmental testing or mechanical testing)	Types of test/ Properties measured	Reference to standardized method (e.g. ISO 14577-1:2003)/ Internal method reference
<b>Paracetamol – Active Pharmaceutical Ingredient</b>	Pharmaceutical Testing	Quantitative Analysis/ Identification and Assay	Internal Method with reference to British Pharmacopoeia (BP) 2020 Volume # 3, Paracetamol Tablets Page # 1086
<b>Ibuprofen - Active Pharmaceutical Ingredient</b>	Pharmaceutical Testing	Quantitative Analysis/ Identification and Assay	Internal Method with reference to United States Pharmacopoeia (USP) 2019 Volume # 1 Ibuprofen Tablets Page # 2235
<b>Paracetamol Tablets</b>	Pharmaceutical Testing	Disintegration	British Pharmacopoeia (BP) 2020 Appendix XII-A V-A384 – V-A388 / United States Pharmacopoeia (USP) 2019, Chapter# 701, Page#6866-6868 / MS
	Pharmaceutical Testing	Uniformity of Mass	British Pharmacopoeia (BP) 2020 / Consistency of formulated preparation / Appendix XII-C V-A408 - V-A410
	Pharmaceutical Testing	Assay of Active Ingredients	British Pharmacopoeia (BP) 2020 Volume#3, Page#1086
<b>Ibuprofen Tablets</b>	Pharmaceutical Testing	Identification	United States Pharmacopoeia (USP) 2019, Volume#1, Page#2235
	Pharmaceutical Testing	Disintegration	British Pharmacopoeia (BP) 2020 Appendix XII-A V-A384 – V-A388 / United States Pharmacopoeia (USP) 2019, Chapter# 701, Page#6866-

**30-04-2020**

Date

Director General

	<b>ACCREDITATION DOCUMENT</b>	<b>F-06/02</b> <b>Issue Date: 10/08/15</b> <b>Rev. No: 07</b> <b>LAB 166</b>
---	-----------------------------------	---

			6868 / MS
	Pharmaceutical Testing	Assay of Active Ingredients	United States Pharmacopoeia (USP) 2019, Volume#1, Page#2235
<b>Metformin Tablets</b>	Pharmaceutical Testing	Uniformity of Mass	British Pharmacopoeia (BP) 2020 / Consistency of formulated preparation / Appendix XII-C V-A408 - V-A410
	Pharmaceutical Testing	Disintegration	British Pharmacopoeia (BP) 2020 Appendix XII-A V-A384 – V-A388 / United States Pharmacopoeia (USP) 2019, Chapter# 701, Page#6866-6868 / MS
	Pharmaceutical Testing	Assay of Active Ingredients	British Pharmacopoeia (BP) 2020, Volume#3, Page# 930-931
<b>Atenolol Tablets</b>	Pharmaceutical Testing	Uniformity of Mass	British Pharmacopoeia (BP) 2020 / Consistency of formulated preparation / Appendix XII-C V-A408 - V-A410
	Pharmaceutical Testing	Disintegration	British Pharmacopoeia (BP) 2020 Appendix XII-A V-A384 – V-A388 / United States Pharmacopoeia (USP) 2019, Chapter# 701, Page#6866-6868 / MS
	Pharmaceutical Testing	Assay of Active Ingredients	British Pharmacopoeia (BP) 2020, Volume#3, Page#174
<b>Ciprofloxacin Tablets</b>	Pharmaceutical Testing	Identification	United States Pharmacopoeia (USP) 2019, Volume#1, Page#996
	Pharmaceutical Testing	Uniformity of Mass	British Pharmacopoeia (BP) 2020 / Consistency of formulated preparation / Appendix XII-C V-A408 - V-A410
	Pharmaceutical Testing	Disintegration	British Pharmacopoeia (BP) 2020 Appendix XII-A V-A384 – V-A388 / United States Pharmacopoeia (USP)

**30-04-2020**

Date

Director General

	<b>ACCREDITATION DOCUMENT</b>	<b>F-06/02</b> <b>Issue Date: 10/08/15</b> <b>Rev. No: 07</b> <b>LAB 166</b>
---	-----------------------------------	---

			2019, Chapter# 701, Page#6866-6868 / MS
	Pharmaceutical Testing	Assay of Active Ingredient (Ciprofloxacin)	United States Pharmacopoeia (USP) 2019, Volume#1, Page#997
<b>Amoxicillin Capsules</b>	Pharmaceutical Testing	Identification	United States Pharmacopoeia (USP) 2019, Volume#1, Page#229
	Pharmaceutical Testing	Uniformity of Mass	British Pharmacopoeia (BP) 2020 / Consistency of formulated preparation / Appendix XII-C V-A408 - V-A410
	Pharmaceutical Testing	Disintegration	British Pharmacopoeia (BP) 2020 Appendix XII-A V-A384 – V-A388 / United States Pharmacopoeia (USP) 2019, Chapter# 701, Page#6866-6868 / MS
	Pharmaceutical Testing	Assay of Active Ingredients	United States Pharmacopoeia (USP) 2019, Volume#1, Page#229
<b>Omeprazole Capsules</b>	Pharmaceutical Testing	Identification	United States Pharmacopoeia (USP) 2019, Volume#2, Page#3224
	Pharmaceutical Testing	Assay of Active Ingredients	United States Pharmacopoeia (USP) 2019, Volume#2, Page#3224
	Pharmaceutical Testing	Uniformity of Mass	British Pharmacopoeia (BP) 2020 / Consistency of formulated preparation / Appendix XII-C V-A408 - V-A410
<b>Ciprofloxacin Injection</b>	Pharmaceutical Testing	Identification	United States Pharmacopoeia (USP) 2019, Volume#1, Page#994
	Pharmaceutical Testing	pH	United States Pharmacopoeia (USP) 2019, Volume#4, Chapter#791, Page#6948-6951 /MS

**30-04-2020**

Date

Director General

	<b>ACCREDITATION DOCUMENT</b>	<b>F-06/02</b> <b>Issue Date: 10/08/15</b> <b>Rev. No: 07</b> <b>LAB 166</b>
---	-----------------------------------	---

	Pharmaceutical Testing	Assay of Active Ingredient	United States Pharmacopoeia (USP) 2019, Volume#1, Page#994
<b>pH of Ceftriaxone Injection</b>	Pharmaceutical Testing	pH	United States Pharmacopoeia (USP) 2019, Volume#4, Chapter#791, Page#6948-6951 /MS
<b>pH of Dexamethasone Sodium Injection</b>	Pharmaceutical Testing	pH	United States Pharmacopoeia (USP) 2019, Volume#4, Chapter#791, Page#6948-6951 /MS
<b>pH of Dopamine Injection</b>	Pharmaceutical Testing	pH	British Pharmacopoeia (BP) 2020, Volume#5, Appendix VI, V-A281 - V-A282 /MS
<b>pH of Naloxone Injection</b>	Pharmaceutical Testing	pH	British Pharmacopoeia (BP) 2020, Volume#5, Appendix VI, V-A281 - V-A282 /MS
<b>pH of Atracurium Injection</b>	Pharmaceutical Testing	pH	United States Pharmacopoeia (USP) 2019, Volume#4, Chapter#791, Page#6948-6951 /MS
<b>Weight Variation of Cetirizine Tablets</b>	Pharmaceutical Testing	Uniformity of weight (mass)	British Pharmacopoeia (BP) 2020 / Consistency of formulated preparation / Appendix XII-C, V-A408 - V-A410
<b>Weight Variation of Moxifloxacin Tablets</b>	Pharmaceutical Testing	Uniformity of weight (mass)	British Pharmacopoeia (BP) 2020 / Consistency of formulated preparation / Appendix XII-C V-A408 - V-A410
<b>Weight Variation of Diclofenac Tablets</b>	Pharmaceutical Testing	Uniformity of weight (mass)	British Pharmacopoeia (BP) 2020 / Consistency of formulated preparation / Appendix XII-C V-A408 - V-A410
<b>Weight Variation of Amlodipine Tablets</b>	Pharmaceutical Testing	Uniformity of weight (mass)	British Pharmacopoeia (BP) 2020 / Consistency of formulated preparation / Appendix XII-C V-A408 - V-A410

**30-04-2020**

Date

Director General



**ACCREDITATION  
DOCUMENT**

**F-06/02**  
**Issue Date: 10/08/15**  
**Rev. No: 07**  
**LAB 166**

<b>Weight Variation of Domperidone Tablets</b>	Pharmaceutical Testing	Uniformity of weight (mass)	British Pharmacopoeia (BP) 2020 / Consistency of formulated preparation / Appendix XII-C V-A408 - V-A410
<b>Disintegration of Carvedilol Tablets</b>	Pharmaceutical Testing	Disintegration	British Pharmacopoeia (BP) 2020 Appendix XII-A V-A384 – V-A388 / United States Pharmacopoeia (USP) 2019, Chapter# 701, Page#6866-6868 / MS
<b>Disintegration of Losartan Tablets</b>	Pharmaceutical Testing	Disintegration	British Pharmacopoeia (BP) 2020 Appendix XII-A V-A384 – V-A388 / United States Pharmacopoeia (USP) 2019, Chapter# 701, Page#6866-6868 / MS
<b>Disintegration of Atorvastatin Tablets</b>	Pharmaceutical Testing	Disintegration	British Pharmacopoeia (BP) 2020 Appendix XII-A V-A384 – V-A388 / United States Pharmacopoeia (USP) 2019, Chapter# 701, Page#6866-6868 / MS
<b>Disintegration of Ramipril Tablets</b>	Pharmaceutical Testing	Disintegration	British Pharmacopoeia (BP) 2020 Appendix XII-A V-A384 – V-A388 / United States Pharmacopoeia (USP) 2019, Chapter# 701, Page#6866-6868 / MS
<b>Disintegration of Prednisolone Tablets</b>	Pharmaceutical Testing	Disintegration	British Pharmacopoeia (BP) 2020 Appendix XII-A V-A384 – V-A388 / United States Pharmacopoeia (USP) 2019, Chapter# 701, Page#6866-6868 / MS
<b>Conductivity of Water for Injection</b>	Pharmaceutical Testing	Conductivity	United States Pharmacopoeia (USP) 2019, Volume#4, Chapter 6517, Page# 6799

**30-04-2020**

Date

Director General